Driving compliance and growth

AI-powered regulatory affairs

US regulatory shifts in biotech and pharma
  • Insight
  • 4 minute read
  • 07/04/25
Dr Sandra Ragaz-Fumia

Dr Sandra Ragaz-Fumia

Partner, Leader Pharma & Life Science – International Indirect Tax & ReguIatory, PwC Switzerland

Dominik Hofstetter

Dominik Hofstetter

Senior Associate, Pharma & Life Science Regulatory, PwC Switzerland

Evolving global regulations in the pharmaceutical and life sciences industries have created a complex web of compliance challenges. Rapidly changing standards from governing bodies like the FDA and EMA, coupled with manual, time-consuming processes, have put regulatory affairs (RA) teams under strain and hindered organisational growth. However, the strategic application of artificial intelligence (AI) offers a transformative solution to these pressing, modern-day issues.

Chapter 1 Barriers to efficiency and expansion

RA professionals and senior management face a myriad of obstacles in their day-to-day business, ranging from rapidly evolving global standards that create compliance gaps to manual processes that increase costs and error risks. The complexity of the diverse regional requirements, together with lengthy approval processes, further complicates market expansion and supply chain efficiency – leading to delays in time-to-market and thus revenue generation.

The high price of inefficiency in regulatory affairs

The financial and reputational consequences of inefficient RA practices can be severe. Penalties for non-compliance, delayed approvals and redundant workflows negatively impact profitability. Errors in submissions or product recalls can damage stakeholder trust and a company’s reputation. Moreover, the disproportionate allocation of RA teams’ time to manual tasks leaves little room for strategic priorities, hindering overall business growth.

Chapter 2 AI to the rescue

AI-powered solutions present a transformative answer to the challenges facing regulatory affairs. Automated document generation, submission tracking and error flagging can reduce manual effort by over 50%. Predictive compliance capabilities using machine learning enable companies to be proactive in carrying out risk assessments and adapting to regulatory changes. AI-driven, global harmonisation streamlines the market-entry process by mapping the diverse regional requirements. Real-time analytics empower enhanced decision-making, optimising resource allocation and submission strategies.

Utilising AI is not without risk

While the potential of AI is clear, it’s crucial to approach its implementation with care and foresight. AI systems are not infallible – they can be susceptible to ‘hallucinations’, whereby plausible-sounding yet inaccurate outputs are produced. This underscores the need for a human lead with oversight and validation of outputs. Additionally, the sensitive nature of regulatory data calls for attention to data security and cybersecurity measures to protect against breaches. Ensuring high-quality, reliable data is also paramount, as the integrity of AI-generated insights and subsequent decision-making hinges on the quality of the underlying information. 

The foundation for lasting impact

Developing a solid business case for AI adoption in regulatory affairs is the key to sustained value for an organisation. The specific needs depend on the company’s set-up and current AI adoption status. A first step could incorporate a cost-benefit analysis. Key ROI drivers might include reduced labour costs, faster approvals and mitigated penalties. For example, a mid-sized pharma company may be able to cut its submission preparation time by 60% and accelerate its time-to-market by 25% through the implementation of AI tools. The implementation roadmap typically involves auditing current workflows, piloting AI solutions and scaling the technology, together with integration support and employee training.

Chapter 3 PwC is your all-in-one expert

PwC, as a global leader in AI-driven solutions, is investing CHF 50 million to expand and scale its capabilities in Switzerland. Our cross-functional subject matter experts in the pharma and life science industry and artificial intelligence guide our clients through the entire journey, from identifying AI-ready processes to ensuring ongoing compliance alignment and tracking tangible ROI metrics. We also provide change management support to upskill RA teams and foster AI adoption within our clients’ organisations.

Getting started

The time to harness the power of AI in regulatory affairs is now. A collaborative, diagnostic audit can help your organisation to identify AI-ready processes and assess the potential for efficiency enhancement. 

PwC is ready to act as your trusted partner in this transformative journey, empowering your RA function to drive compliance, efficiency and strategic growth. Our experts look forward to talking with you in person.

Chapter 4 FAQ

A: The primary benefits of AI in regulatory affairs include reduced manual effort, improved compliance, enhanced decision-making and accelerated time-to-market. AI-powered solutions can automate documentation, track regulatory changes, harmonise global requirements and provide real-time analytics for optimising resource allocation and submission strategies.

A: PwC provides support throughout the AI implementation journey. This includes expertise in identifying AI-ready processes, piloting and scaling AI solutions, ensuring ongoing compliance alignment and tracking tangible ROI metrics. Additionally, we support our clients with change management guidance to help them upskill their RA teams and foster AI adoption within the organisation.

A: The first step in building a business case is to conduct a thorough cost-benefit analysis. This involves identifying the ROI drivers, such as reduced labour costs, faster approvals and avoidance of penalties. The implementation roadmap typically includes auditing current workflows, piloting AI tools and scaling the solutions, together with integration support and employee training.

Contact us

Dr Sandra Ragaz-Fumia

Partner, Leader Pharma & Life Science – International Indirect Tax & ReguIatory, PwC Switzerland

+41 79 792 72 98

Email

Jean-Pierre Anzevui

Director, Pharma & Life Sciences – International Indirect Tax & Regulatory, PwC Switzerland

+41 58 792 93 08

Email

Dominik Hofstetter

Senior Associate, Pharma & Life Science Regulatory, PwC Switzerland

+41 58 792 49 05

Email